EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma

Peng Sun iD, Yajun Li, Cong Li, Kexing Ren, Yu Wang, Hang Yang, Wenqi Jiang, Liqun Zou, Haiyan Yang, Hui Zhou, Zhi-Ming Li iD

American Journal of Hematology · 2023-07 · 98 (7) · 1043-1051

DOI: 10.1002/ajh.26922 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 07.04.2023. Verfasst von Peng Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel highly effective and low‐toxicity combination therapy for localized extranodal natural‐killer/T‐cell lymphoma (ENKTL) remains a clinically unmet need. This phase II trial (NCT03936452) investigated the efficacy and safety of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line treatment in patients with newly‐diagnosed stage I–II ENKTL. The patients received sintilimab 200 mg plus pegaspargase 2500 U/m 2 on day 1 and anlotinib 12 mg once daily on days 1–14 for three 21‐day cycles, followed by intensity‐modulated radiotherapy and another three cycles of systemic therapy. The primary endpoint was the complete response rate (CRR) after six treatment cycles. The secondary endpoints included progression‐free survival (PFS), overall survival (OS), CRR after two cycles, overall response rate (ORR) after six cycles, duration of response (DOR), and safety. Between May 2019 and July 2021, 58 patients were enrolled. The CRR was 55.1% (27/49) after two cycles and 87.8% (43/49) after six cycles. The ORR was 87.8% (43/49; 95% CI, 75.2–95.4) after six cycles. After a median follow‐up of 22.5 months (95% CI, 20.4–24.6), the median PFS, OS, and DOR were not reached. The 2‐year PFS, OS, and DOR rates were 87.6% (95% CI, 78.8–97.4), 97.9% (95% CI, 94.0–100), and 91.1% (95% CI, 83.2–99.8), respectively. Grade 3–4 treatment‐related adverse events occurred in 41.4% (24/58) of patients, with the most common being hypertension (15.5%), hypertriglyceridemia (8.6%), oral mucositis (6.9%), and anemia (5.2%). No treatment‐related deaths occurred. First‐line sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy demonstrated promising efficacy in treatment‐naïve early‐stage ENKTL patients with a favorable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Extranodal NK-T-CellHumansAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineAsparaginasePolyethylene GlycolsIndolesQuinolinesAntibodies, Monoclonal, Humanized

Substanzen

DeoxycytidinepegaspargaseAsparaginasePolyethylene GlycolsanlotinibIndolesQuinolinessintilimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
  • Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, 410013, China.
  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410000, China.
  • Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, 310012, China.
  • Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China.

ORCID-Profile: Peng Sun, Zhi-Ming Li

Förderung

  • National Natural Science Foundation of China
  • National Science and Technology Major Project

Zitieren

APA

Sun, P., Li, Y., Li, C., Ren, K., Wang, Y., Yang, H., Jiang, W., Zou, L., Yang, H., Zhou, H., & Li, Z. M. (2023). A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma. American Journal of Hematology, 98(7), 1043-1051. https://doi.org/10.1002/ajh.26922

Vancouver

Sun P, Li Y, Li C, Ren K, Wang Y, Yang H, et al. A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma. American Journal of Hematology. 2023;98(7):1043-1051. doi:10.1002/ajh.26922

BibTeX
@article{Sun2023,
  author = {Sun, Peng and Li, Yajun and Li, Cong and Ren, Kexing and Wang, Yu and Yang, Hang and Jiang, Wenqi and Zou, Liqun and Yang, Haiyan and Zhou, Hui and Li, Zhi-Ming},
  title = {A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {7},
  pages = {1043--1051},
  doi = {10.1002/ajh.26922}
}
Kostenlos starten →